Glaukos Reports Q4 Earnings Loss

Got story updates? Submit your updates here. ›

Glaukos Corp., a California-based glaucoma treatments developer, reported a loss of $133.7 million in its fourth quarter. On a per-share basis, the company had a loss of $2.32, though losses adjusted for asset impairment costs came to 28 cents per share, missing Wall Street expectations. However, the company posted revenue of $143.1 million in the period, topping Street forecasts.

Why it matters

Glaukos is a key player in the glaucoma treatments market, so its financial performance is closely watched by investors and industry analysts. The company's wider-than-expected loss, despite higher revenue, suggests it may be facing challenges in its operations or product development that are impacting its bottom line.

The details

Glaukos reported a loss of $133.7 million in the fourth quarter, or $2.32 per share. Adjusted for asset impairment costs, the loss was 28 cents per share, missing the average analyst estimate of a 22-cent loss. However, the company's revenue of $143.1 million topped the $142.9 million expected by analysts. For the full year, Glaukos reported a loss of $187.7 million, or $3.28 per share, on revenue of $507.4 million.

• Glaukos reported its Q4 and full-year 2025 financial results on February 17, 2026.

What’s next

Glaukos expects to report full-year 2026 revenue in the range of $600 million to $620 million.